These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12371084)

  • 1. [Severe electrolyte imbalance and edema in therapy with rosiglitazone].
    Kuschel U; Hesselbarth N; Herrmann A; Hippius M; Hoffmann A
    Med Klin (Munich); 2002 Sep; 97(9):553-5. PubMed ID: 12371084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular injury in a patient receiving rosiglitazone. A case report.
    Al-Salman J; Arjomand H; Kemp DG; Mittal M
    Ann Intern Med; 2000 Jan; 132(2):121-4. PubMed ID: 10644273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
    Krentz AJ; Bailey CJ; Melander A
    BMJ; 2000 Jul; 321(7256):252-3. PubMed ID: 10915108
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.
    Lebovitz HE; Kreider M; Freed MI
    Diabetes Care; 2002 May; 25(5):815-21. PubMed ID: 11978674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone-induced granulomatous hepatitis.
    Dhawan M; Agrawal R; Ravi J; Gulati S; Silverman J; Nathan G; Raab S; Brodmerkel G
    J Clin Gastroenterol; 2002; 34(5):582-4. PubMed ID: 11960075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver failure in a patient treated with long-term rosiglitazone therapy.
    Gouda HE; Khan A; Schwartz J; Cohen RI
    Am J Med; 2001 Nov; 111(7):584-5. PubMed ID: 11705443
    [No Abstract]   [Full Text] [Related]  

  • 7. Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone.
    Bonkovsky HL; Azar R; Bird S; Szabo G; Banner B
    Dig Dis Sci; 2002 Jul; 47(7):1632-7. PubMed ID: 12141828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatotoxicity with thiazolidinediones: is it a class effect?
    Scheen AJ
    Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of rosiglitazone-induced edema: two case reports and a review of the literature.
    Wang F; Aleksunes LM; Reagan LA; Vergara CM
    Diabetes Technol Ther; 2002; 4(4):505-14. PubMed ID: 12396745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitis.
    Lenhard MJ; Funk WB
    Diabetes Care; 2001 Jan; 24(1):168-9. PubMed ID: 11194222
    [No Abstract]   [Full Text] [Related]  

  • 11. Rosiglitazone toxicity.
    Ravinuthala RS; Nori U
    Ann Intern Med; 2000 Oct; 133(8):658. PubMed ID: 11033603
    [No Abstract]   [Full Text] [Related]  

  • 12. Postmarketing pharmacovigilance of adverse drug reactions: the case of rosiglitazone in Mexico.
    Reyes-Morales H; Mino-León D; Doubova SV; Flores-Hernández S
    Int J Clin Pharmacol Ther; 2012 Jan; 50(1):1-9. PubMed ID: 22192639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pioglitazone].
    Kobayashi M; Iwata M; Hiratani K
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():429-37. PubMed ID: 12387029
    [No Abstract]   [Full Text] [Related]  

  • 14. Hepatic injury due to troglitazone.
    Malik AH; Prasad P; Saboorian MH; Thiele DL; Malet PF
    Dig Dis Sci; 2000 Jan; 45(1):210-4. PubMed ID: 10695637
    [No Abstract]   [Full Text] [Related]  

  • 15. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
    Wolffenbuttel BH; Gomis R; Squatrito S; Jones NP; Patwardhan RN
    Diabet Med; 2000 Jan; 17(1):40-7. PubMed ID: 10691158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction: Liver injury and rosiglitazone.
    Ann Intern Med; 2000 Aug; 133(3):237. PubMed ID: 10906846
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe but reversible hepatitis induced by troglitazone.
    Schiano T; Dolehide K; Hart J; Baker AL
    Dig Dis Sci; 2000 May; 45(5):1039-42. PubMed ID: 10795774
    [No Abstract]   [Full Text] [Related]  

  • 18. Thiazolidinedione hepatotoxicity: a class effect?
    Tolman KG
    Int J Clin Pract Suppl; 2000 Oct; (113):29-34. PubMed ID: 11965828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated hypertension due to rosiglitazone therapy.
    Vikram NK; Misra A; Devi JR
    Indian Heart J; 2002; 54(6):733. PubMed ID: 12674195
    [No Abstract]   [Full Text] [Related]  

  • 20. Isolated elevation of alkaline phosphatase level associated with rosiglitazone.
    Hachey DM; O'Neil MP; Force RW
    Ann Intern Med; 2000 Nov; 133(9):752. PubMed ID: 11074926
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.